title: Isolation and genome-wide expression and methylation characterization of CD31+ cells from normal and malignant human prostate tissue.
abstract: Endothelial cells (ECs) are an important component involved in the angiogenesis. Little is known about the global gene expression and epigenetic regulation in tumor endothelial cells. The identification of gene expression and epigenetic difference between human prostate tumor-derived endothelial cells (TdECs) and those in normal tissues may uncover unique biological features of TdEC and facilitate the discovery of new anti-angiogenic targets. We established a method for isolation of CD31+ endothelial cells from malignant and normal prostate tissue obtained at prostatectomy. TdECs and normal-derived ECs (NdECs) showed >90% enrichment in primary culture and demonstrated microvascular endothelial cell characteristics such as cobblestone morphology in monolayer culture, diI-acetyl-LDL uptake and capillary-tube like formation in Matrigel®. In vitro primary cultures of ECs maintained expression of endothelial markers such as CD31, von Willebrand factor, intercellular adhesion molecule, vascular endothelial growth factor receptor 1, and vascular endothelial growth factor receptor 2. We then conducted a pilot study of transcriptome and methylome analysis of TdECs and matched NdECs from patients with prostate cancer. We observed a wide spectrum of differences in gene expression and methylation patterns in endothelial cells, between malignant and normal prostate tissues. Array-based expression and methylation data were validated by qRT-PCR and bisulfite DNA pyrosequencing. Further analysis of transcriptome and methylome data revealed a number of differentially expressed genes with loci whose methylation change is accompanied by an inverse change in gene expression. Our study demonstrates the feasibility of isolation of ECs from histologically normal prostate and prostate cancer via CD31+ selection. The data, although preliminary, indicates that there exist widespread differences in methylation and transcription between TdECs and NdECs. Interestingly, only a small proportion of perturbed gene was overlapped between American (AA) and Caucasian American (CA) patients with prostate cancer. Our study indicates that identifying gene expression and/or epigenetic differences between TdECs and NdECs may provide us with new anti-angiogenic targets. Future studies will be required to further characterize the isolated ECs and determine the biological features that can be exploited in the prognosis and therapy of prostate cancer.
authors: Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York.
authors: Wei
authors: W
authors: Luo
authors: Qiang
authors: Q
authors: Hu
authors: Dan
authors: D
authors: Wang
authors: Kristin K
authors: KK
authors: Deeb
authors: Yingyu
authors: Y
authors: Ma
authors: Carl D
authors: CD
authors: Morrison
authors: Song
authors: S
authors: Liu
authors: Candace S
authors: CS
authors: Johnson
authors: Donald L
authors: DL
authors: Trump
mesh_terms: D002454:Cell Differentiation / Q000502:physiology; D019175:DNA Methylation; D042783:Endothelial Cells / Q000378:metabolism / Q000473:pathology; D020869:Gene Expression Profiling; D055106:Genome-Wide Association Study; D006801:Humans; D008297:Male; D046228:Microarray Analysis; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000235:genetics* / Q000378:metabolism; D011467:Prostate / Q000378:metabolism / Q000473:pathology; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology
chemical_list: D019408:Platelet Endothelial Cell Adhesion Molecule-1
references: Science. 1998 Jan 16;279(5349):377-80
references: 9430587
references: Nat Rev Cancer. 2002 Oct;2(10):727-39
references: 12360276
references: J Clin Invest. 1998 Jul 15;102(2):430-7
references: 9664085
references: Nat Biotechnol. 1997 Jun;15(6):542-6
references: 9181576
references: J Clin Oncol. 2007 Mar 1;25(7):852-61
references: 17327606
references: Nat Rev Cancer. 2003 Jun;3(6):401-10
references: 12778130
references: Int J Oncol. 2009 Oct;35(4):751-60
references: 19724911
references: Am J Pathol. 2004 Aug;165(2):601-8
references: 15277233
references: Front Biosci (Landmark Ed). 2009 Jan 01;14:3962-73
references: 19273326
references: Nat Rev Genet. 2002 Jun;3(6):415-28
references: 12042769
references: Science. 2000 Aug 18;289(5482):1197-202
references: 10947988
references: J Pathol. 2007 Feb;211(3):269-77
references: 17139617
references: Cancer Sci. 2008 Mar;99(3):459-66
references: 18167133
references: Nat Rev Cancer. 2008 Aug;8(8):579-91
references: 18596824
references: Am J Pathol. 2000 Apr;156(4):1363-80
references: 10751361
references: Cancer Res. 2008 Feb 1;68(3):927-36
references: 18245496
references: J Transl Med. 2006 Mar 02;4:13
references: 16512911
references: Cancer Res. 2004 Nov 15;64(22):8249-55
references: 15548691
references: N Engl J Med. 2004 Jun 3;350(23):2335-42
references: 15175435
references: Expert Opin Biol Ther. 2009 Apr;9(4):507-17
references: 19344286
references: Hum Mol Genet. 2001 Jun 15;10(13):1413-9
references: 11440994
references: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references: 22237781
references: Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8
references: 12516034
references: Cancer Res. 2006 Sep 1;66(17):8565-73
references: 16951169
references: Epigenetics. 2011 Aug;6(8):994-1000
references: 21725204
references: Infect Agent Cancer. 2009 Feb 10;4 Suppl 1:S3
references: 19208208
references: J Natl Cancer Inst. 2006 Feb 15;98(4):255-61
references: 16478744
references: Am J Pathol. 2009 Dec;175(6):2657-67
references: 19875502
references: Nat Rev Cancer. 2008 Aug;8(8):592-603
references: 18650835
references: Endocrinology. 2008 Jun;149(6):2959-69
references: 18292195
references: Int J Oncol. 2010 Jun;36(6):1379-86
references: 20428760
references: Cancer Metastasis Rev. 2003 Mar;22(1):83-6
references: 12716039
references: Prostate. 2011 Jun 15;71(9):985-97
references: 21541975
references: Med Res Rev. 2010 Jan;30(1):23-66
references: 19536866
references: Nat Rev Clin Oncol. 2011 Mar 01;8(4):210-21
references: 21364524
references: Cancer Res. 2004 Nov 1;64(21):7857-66
references: 15520192
references: Nat Med. 1999 Sep;5(9):1032-8
references: 10470080
references: Nature. 2005 Dec 15;438(7070):932-6
references: 16355210
references: N Engl J Med. 2003 Jul 31;349(5):427-34
references: 12890841
references: Cancer Res. 2006 Feb 15;66(4):2173-80
references: 16489018
references: Int J Oncol. 2010 Jan;36(1):5-18
references: 19956828
references: Biochem Biophys Res Commun. 2010 Apr 16;394(4):947-54
references: 20302845
references: Immunol Invest. 2007;36(1):3-23
references: 17190647
references: Br J Cancer. 2011 Mar 1;104(5):819-29
references: 21285980
references: N Engl J Med. 1971 Nov 18;285(21):1182-6
references: 4938153
references: PLoS One. 2012;7(10):e44294
references: 23056178
references: Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S127-33
references: 14508090
references: Curr Opin Genet Dev. 2005 Feb;15(1):102-11
references: 15661540
references: Semin Oncol. 2001 Dec;28(6):536-42
references: 11740806
references: Cell. 2000 Jan 7;100(1):57-70
references: 10647931
references: Cancer Res. 2008 Nov 1;68(21):8954-67
references: 18974140
references: Nat Rev Drug Discov. 2007 Apr;6(4):273-86
references: 17396134
references: Am J Clin Oncol. 2014 Jun;37(3):289-96
references: 22772426
references: Cancer. 2006 Mar 15;106(6):1276-85
references: 16475208
references: Prostate. 2009 May 15;69(7):770-3
references: 19204997
references: Carcinogenesis. 2006 Sep;27(9):1883-93
references: 16624828
references: J Cell Biol. 1984 Dec;99(6):2034-40
references: 6501412
references: Cancer Sci. 2009 Oct;100(10):1963-70
references: 19650861
references: Am J Pathol. 2008 May;172(5):1381-90
references: 18403594
references: BJU Int. 2012 Dec;110(11 Pt C):E794-808
references: 22958524